Status:
TERMINATED
Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C
Lead Sponsor:
Seoul National University Boramae Hospital
Conditions:
Depression
Eligibility:
All Genders
20-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the anti-depressive efficacy of mirtazapine in depression induced by peginterferon alpha-2a and ribavirin treatment in Korean patients with chronic hepatitis C...
Detailed Description
Depression is a common serious adverse event (30%-50%) during the interferon treatment for chronic hepatitis C. Adequate control of depressive symptoms might enable to adhere to antiviral therapy and ...
Eligibility Criteria
Inclusion
- Major depressive episode diagnosed with Diagnostic and Statistical Manual Diploma in Social Medicine-IV (DSM-IV)
- Hamilton Depression Scale (HAMD-17) ≥ 14
Exclusion
- Any other axis I primary diagnoses except major depressive disorder
- Having serious adverse events or hypersensitivity to mirtazapine
- Having major depressive disorder prior to the first injection of interferon
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01465919
Start Date
August 1 2011
End Date
March 1 2018
Last Update
March 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SMG-SNU Boramae Medical Center
Seoul, South Korea, 156-707